Fri, May 10, 2024

Keay Nakae Maintained (ARWR) at Strong Buy and Held Target at $60 on, May 10th, 2024


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. -buy-and-held-target-at-60-on-may-10th-2024.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Keay Nakae of Chardan Capital, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $60 on, May 10th, 2024.

Keay has made no other calls on ARWR in the last 4 months.



There are 4 other peers that have a rating on ARWR. Out of the 4 peers that are also analyzing ARWR, 2 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Shawn Egan of "Citigroup" Maintained at Hold with Increased Target to $34 on, Wednesday, February 7th, 2024
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $36 on, Wednesday, February 7th, 2024


These are the ratings of the 2 analyists that currently disagree with Keay


  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Thursday, February 8th, 2024
  • Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $50 on, Wednesday, February 7th, 2024

Publication Contributing Sources